Molecular Formula | C23H14ClFN2O2 |
Molar Mass | 404.82 |
Solubility | DMSO : 26 mg/mL (64.23 mM) |
Storage Condition | under inert gas (nitrogen or Argon) at 2-8°C |
In vitro study | This response is not regulated by mTOR signaling SBI-756 to the combination of disrupting the eIF4F complex. It reduces the growth rate of BRAF-resistant and BRAF-dependent melanomas. SBI-756 also inhibits the AKT and NF-kB signaling pathways, inhibiting the growth of melanoma bearing mutations in NRAS, BRAF, and NF1 in vitro. |
In vivo study | SBI-756 delay the onset and reduce the incidence of Nras/Ink4a melanoma in vivo. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.47 ml | 12.351 ml | 24.702 ml |
5 mM | 0.494 ml | 2.47 ml | 4.94 ml |
10 mM | 0.247 ml | 1.235 ml | 2.47 ml |
5 mM | 0.049 ml | 0.247 ml | 0.494 ml |
biological activity | SBI-0640756 is the first inhibitor targeting eIF4G1, which can destroy eIF4F complex. |
Target | Value |